Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 475-479

  Suzuki, Yoshimasa ^a   Ishibiki, Yoshiro ^a   Kawai, Ken ^a   Sasaki, Morio ^a   Matsuda, Mitsuhiro ^a   Watanabe, Tomoo ^a   Shirasaka, Tetsuhiko ^b   Kamano, Toshiki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Experimental study; Low dose cisplatin; TS 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; FLUOROURACIL; OXONATE POTASSIUM; TEGAFUR; TS 1; UNCLASSIFIED DRUG; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; ERYTHROCYTE COUNT; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SARCOMA 180; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FLUOROURACIL; MALE; MICE; OXONIC ACID; PYRIDINES; SARCOMA 180; TEGAFUR; TISSUE DISTRIBUTION;

EID: 0041625819     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00014     Document Type: Article

References (22)

1. Kondo K, Murase M, Kodera Y, Akiyama S, Ito K, Yokoyama Y, et al. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 1996; 53:64-67.
2. Chung Y, Yamashita Y, Matsuoka T, Nakata B, Onoda N, Maeda K, et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997; 80:1-7.
3. Kondo K, Akiyama S, Kasai Y, Kato S, Kuno Y, Kataoka M, et al. Antitumor effect of S-1 and cisplatin treatment against human gastric cancer xenografted in nude mice. Jpn J Cancer Chemother 1997; 24:1103-1108.
4. Sasaki K, Hirata K, Denno R, Oikawa I, Mukaiya M, Hiraike N, et al. Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma. Jpn J Cancer Chemother 1997; 24:959-964.
5. Sasaki K, Hirata K, Takasaka H, Hiraike N, Katsuramaki T, Oikawa I, et al. Combination chemotherapy of continuous infusion 5-FU and cisplatin for advanced colorectal cancer: a Sapporo Cancer Study (SACS) trial. Proc Am Soc Clin Oncol 1997; 16:269a (abstr 955).
6. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Sawada T, Karo Y, et al. Continuous 5-FU and low-dose cisplatin for advanced and recurrent gastric cancer. Proc Am Soc Clin Oncol 1997; 16:285a (abstr 1011).
7. Kondo K, Kataoka M, Ichihara T, Horisawa M, Kasai Y, Akiyama S, et al. Neoadjuvant chemotherapy for metastatic gastric cancer with 5-fluorouracil and repeated low dose cisplatin: a pilot study. Proc Am Soc Clin Oncol 1997; 16:294a (abstr 1046).
8. Kamano T, Mikami Y, Shirasaka T. Continuous infusion of 5-fluorouracil plus low-dose cisplatin in tumor-bearing mice. Anticancer Drugs 1997; 8:632-636.
9. Hirata K, Mukaiya M, Yamamitsu S, Oikawa I, Takashima T, Katsuramaki T, et al. Biochemical modulation therapy for pancreatic cancer. J Hepatobilary Pancreat Surg 1998; 5:225-260.
10. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluolouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83:8923-8925.
11. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor moders in vivo. Cancer Chemother Pharmacol 1993; 32:167-172.
12. Araki H, Fukushima M, Kamiyama Y, Shirasaka T. Effect consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett 2000; 169:185-191.
13. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion of fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7:425-432.
14. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
15. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53:4004-4009.
16. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil by two biochemical modulator. Anticancer Drugs 1996; 7:548-557.
17. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56:2602-2606.
18. Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T. Conceptual changes in cancer chemotherapy from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrugs, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000; 18:315-329.
19. Fujii S, Shimamoto Y, Ohshimo H, Imaoka T, Motoyama M, Fukushima M, et al. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation of Yoshida sarcoma in rats. Jpn J Cancer Res 1989; 89:167-172.
20. Konishi K, Yabushita K, Taguchi T, Ohta J, Takashima S, Abe T, et al. Late phase I trial of L-leucovorin and 5-fluorouracil in advanced colorectal cancer. Jpn J Cancer Chemother 1995; 22:925-932.
21. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
22. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58:191-197.